Bayer Peru S.A.
More than five decades ago, in 1947, Bayer AG in Leverkusen acquired a stake in SOCOLAN S.A., Sociedad Cornejo Landázuri S.A., which marked the official start of Bayer's commercial activities in Peru.
After a period of flourishing expansion and in view of the economic and political context that the country went through in the 1980s, the production plants were sold. In 1986, the company's name was changed to Bayer Perú S.A.
In 1994 Peru participated in the regionalization process of Bayer within the Andean Group and joined Colombia and Ecuador.
In 1996 the company began a process of expansion and reactivation with the operation of the divisions Consumer Care, Crop Protection and Animal Health, Industrial, Specialty Products, Haarmann & Reimer, Pharma and Agfa. In 1997, the name Bayer S.A. was changed to Bayer S.A.
In Peru, Bayer markets its pharmaceutical, consumer care, industrial, crop protection and animal health products, with which it is present in the development of the country.
Through its Crop Protection Division and its team of professionals, it carries out extension work and technical advisory services in crop management that contribute to the advancement of Peruvian agriculture.
Likewise, within the Pharma Division is the Diagnostics sector, which offers advice for the installation of medical equipment, research and analysis of the highest technology that promote the advancement of medicine in the country.
Towards the future Bayer in Peru will continue expanding its activities and providing through its professionals a consultancy and accompaniment to the different economic activities, to contribute in the adoption of products and methods that help to the development and protect the environment.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in Spanish can be found here.
- Focus : Manufacturer
- Industry : Pharma
Products from Bayer
News about Bayer
08-Mar-2023 | Cooperation
New organ-on-chip pilot seeks to reduce animal testing in consumer health industry
A first-of-its-kind collaboration in the consumer health industry is developing a platform aimed at reducing or replacing animal testing using “organ-on- ...
28-Feb-2023 | Finances
Bayer: Significant growth in sales and earnings
The Bayer Group achieved strong growth last year, posting significantly higher sales and earnings. “2022 was a very successful year for Bayer despite the ...
09-Feb-2023 | People
Bill Anderson to become CEO of Bayer AG
The Supervisory Board of Bayer AG has appointed Bill Anderson to become CEO of Bayer, effective June 1, 2023. He will join Bayer as a member of the Board ...
12-Jan-2023 | Cooperation
Bayer to Accelerate Drug Discovery with Google Cloud’s High-Performance Compute Power
Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud’s Tensor Processing Units (TPUs), which are ...
12-Jan-2023 | Finances
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B ...
14-Nov-2022 | Business
Bayer Acquires German Biotech Start-up Targenomix
Bayer announced the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) ...
08-Nov-2022 | Finances
Bayer with continued strong performance
The Bayer Group maintained its strong business performance across all three divisions in the third quarter. “Despite rising inflation and global supply ...